New cancer therapies: how workforce capacity impacts treatment implementation

New cancer therapies: how workforce capacity impacts treatment implementation

For his guest blog, Dr Martin Rolles explores how lack of workforce planning and specialist training can be a barrier to implementing new cancer therapies.
Read More
Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Nikie Jervis explores the history of regulatory approval for radioligand therapy in the UK, and the importance of patient involvement, in her guest blog.
Read More
Breaking down the inequalities that limit access to radioligand therapy

Breaking down the inequalities that limit access to radioligand therapy

In this guest blog, Dr John Buscombe discusses the difficulties that people with cancer have accessing radioligand therapy in the UK.
Read More
Lessons learned as a radioligand therapy patient

Lessons learned as a radioligand therapy patient

In this guest blog, Josh Mailman recalls his experience of receiving radioligand therapy and the barriers to widespread access for patients.
Read More
Why a framework? The importance of a systems approach for radioligand therapy

Why a framework? The importance of a systems approach for radioligand therapy

The Radioligand Therapy Readiness Assessment Framework is a robust tool which can be used to generate information about integration of radioligand therapy into the health system.
Read More
What is our vision of readiness for radioligand therapy?

What is our vision of readiness for radioligand therapy?

Assessing current integration and readiness for radioligand therapy will help us plan for its effective use.
Read More